Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.58 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.58 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 5/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 5/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027837 | 0.87 | PARP10 (0.63) | PARP10PARP11MKNK1PARP1PDPK1 | |
| SCHEMBL24783703 | 0.83 | PARP10 (0.63) | PARP10PARP11MKNK1PARP1PDPK1 | |
| SCHEMBL23432222 | 0.80 | PARP10 (0.58) | PARP10PARP11MKNK1PARP1PDPK1 | |
| SCHEMBL25124551 | 0.80 | PARP10 (0.58) | PARP10PARP11MKNK1PARP1PDPK1 | |
| SCHEMBL15727824 | 0.77 | PARP10 (0.64) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL23657097 | 0.75 | PARP10 (0.65) | PARP10PARP11MKNK1PARP1PDPK1 | |
| SCHEMBL1951410 | 0.75 | PARP11 (0.63) | PARP10PARP11MKNK1PARP1PDPK1 | |
| SCHEMBL24784236 | 0.74 | MKNK1 (0.48) | PARP10PARP11MKNK1PARP1PDPK1 | |
| SCHEMBL25124517 | 0.74 | PARP10 (0.51) | PARP10PARP11MKNK1PARP1PDPK1 | |
| SCHEMBL15727792 | 0.74 | PARP10 (0.51) | PARP10PARP11MKNK1PARP1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| EP-2089367-B1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2089367-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008053300-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008041037-A1 | FUSED INDOLES AND INDAZOLES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-04-10 | — | — | WO | disclosed |
| EP-1252161-A1 | PYRROLO-ISOQUINOLINE AND TETRAHYDROPYRROLO-ISOQUINOLINE DERIVATIVES AND THEIR USE AS MEDIATORS OF THE 5-HT7 RECEPTOR | Wyeth (US) | 2002-10-30 | — | — | EP | disclosed |
| US-6432974-B1 | CIRCADIAN RHYTHYM, SLEEP, SEXUAL, NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS; DRUG ABUSE, DRUG DEPENDENCE, AND SCHIZOPHRENIA TREATMENT | WYETH | 2002-08-13 | — | — | US | disclosed |
| WO-2001057039-A1 | PYRROLO-ISOQUINOLINE AND TETRAHYDROPYRROLO-ISOQUINOLINE DERIVATIVES AND THEIR USE AS MEDIATORS OF THE 5-HT7 RECEPTOR | WYETH (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | PARP10 579/4885PARP11 596/4885MKNK1 2730/4885 |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | PARP10 579/4885PARP11 596/4885MKNK1 2730/4885 |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | REN, F3, EDNRB | PARP10 3374/4885PARP11 4130/4885MKNK1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.